Publications by authors named "Alfred Zimmerlin"

14Publications

New Perspectives on Drug-Induced Liver Injury Risk Assessment of Acyl Glucuronides.

Chem Res Toxicol 2020 Jul 29;33(7):1551-1560. Epub 2020 Jun 29.

PK Sciences, Novartis Institutes for Biomedical Research, Novartis Campus, 4052 Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.chemrestox.0c00131DOI Listing
July 2020

Design of Potent and Selective Covalent Inhibitors of Bruton's Tyrosine Kinase Targeting an Inactive Conformation.

ACS Med Chem Lett 2019 Oct 6;10(10):1467-1472. Epub 2019 Sep 6.

Global Discovery Chemistry, Autoimmunity, Transplantation & Inflammation, Chemical Biology & Therapeutics, and PK Sciences, Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acsmedchemlett.9b00317DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6792172PMC
October 2019

CYP3A time-dependent inhibition risk assessment validated with 400 reference drugs.

Drug Metab Dispos 2011 Jun 7;39(6):1039-46. Epub 2011 Mar 7.

Discovery ADME, Novartis Institutes for BioMedical Research, WSJ-350.3.12, P.O. Box, CH-4002 Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.110.037911DOI Listing
June 2011

CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis.

Drug Metab Dispos 2011 Feb 2;39(2):191-8. Epub 2010 Nov 2.

Novartis Institutes for BioMedical Research, Drug Metabolism and Pharmacokinetics, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.110.035378DOI Listing
February 2011

Metabolic soft spot identification and compound optimization in early discovery phases using MetaSite and LC-MS/MS validation.

J Med Chem 2009 Jan;52(2):329-35

Novartis Institutes for BioMedical Research, Metabolism and Pharmacokinetics, Postfach, CH-4002, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/jm8008663DOI Listing
January 2009

Evaluation of fluorescence- and mass spectrometry-based CYP inhibition assays for use in drug discovery.

J Biomol Screen 2008 Jun 12;13(5):343-53. Epub 2008 May 12.

ADME Profiling Cambridge, Metabolism and Pharmacokinetics, Global Discovery Chemistry, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1087057108317480DOI Listing
June 2008

High-throughput in vitro profiling assays: lessons learnt from experiences at Novartis.

Expert Opin Drug Metab Toxicol 2006 Dec;2(6):823-33

Novartis Institutes for BioMedical Research, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/17425255.2.6.823DOI Listing
December 2006

SAR of 2,6-diamino-3,5-difluoropyridinyl substituted heterocycles as novel p38MAP kinase inhibitors.

Bioorg Med Chem Lett 2002 Aug;12(16):2109-12

Arthritis and Bone Research, Novartis Pharma AG, CH-4002, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0960-894x(02)00336-0DOI Listing
August 2002